1. Home
  2. CANG vs BDTX Comparison

CANG vs BDTX Comparison

Compare CANG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cango Inc.  each representing two (2)

CANG

Cango Inc. each representing two (2)

SELL

Current Price

$3.05

Market Cap

116.5M

Sector

Technology

ML Signal

SELL

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

SELL

Current Price

$1.78

Market Cap

104.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CANG
BDTX
Founded
2010
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.5M
104.0M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
CANG
BDTX
Price
$3.05
$1.78
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
$6.25
★ $10.00
AVG Volume (30 Days)
★ 1.0M
570.9K
Earning Date
11-30-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 130.71
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$39.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$1.60
52 Week High
$4.53
$4.94

Technical Indicators

Market Signals
Indicator
CANG
BDTX
Relative Strength Index (RSI) 60.53 36.51
Support Level $1.86 $1.61
Resistance Level N/A $1.90
Average True Range (ATR) 0.35 0.08
MACD 0.09 -0.01
Stochastic Oscillator 52.46 2.50

Price Performance

Historical Comparison
CANG
BDTX

About CANG Cango Inc. each representing two (2)

Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The operations are divided into two reportable segments (i) Bitcoin Mining Business and (ii) International Automobile Trading Business. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: